Probiotics as Mitochondrial Modulators: Implications for Health and Disease

A complete illustrated chapter with integrated Vancouver-style references

Probiotics as Mitochondrial Modulators: Implications for Health and Disease

Abstract

Mitochondria are no longer understood only as cellular “powerhouses.” They are metabolic control centers that integrate energy production, redox signaling, apoptosis, inflammatory tone, and adaptation to environmental stress. In parallel, the gut microbiota has emerged as a major regulator of host physiology through production of short-chain fatty acids, bile-acid derivatives, tryptophan metabolites, vitamins, and immunomodulatory compounds. The modern concept of a microbiota–mitochondria axis brings these two fields together by proposing that microbial ecology and mitochondrial biology are functionally linked across multiple scales, from intracellular signaling to whole-body metabolism and aging. Probiotics are one of the few practical tools available to intentionally modulate that axis. This chapter reviews how probiotics may influence mitochondrial function through antioxidant defense, mitochondrial biogenesis, nutrient-sensing pathways, mitophagy, mitochondrial unfolded protein response, and mitonuclear communication. It then examines how these mechanisms may affect aging biology, neurodegeneration, cardiometabolic disease, kidney injury, and intestinal barrier dysfunction. Human evidence is still early, uneven, and often indirect, but it is increasingly consistent with the idea that probiotics can shift metabolic and inflammatory states in ways that are favorable to mitochondrial resilience. The central conclusion is cautious but significant: probiotics are not universal mitochondrial therapies, yet the evidence is now strong enough to treat microbiota-directed mitochondrial support as a serious scientific and translational field rather than a speculative one [1-12].

1. Introduction

For decades, mitochondrial biology and microbiome science developed largely as separate disciplines. Mitochondrial research focused on oxidative phosphorylation, respiratory-chain defects, reactive oxygen species, apoptosis, and inherited metabolic disease. Microbiome research focused on digestion, immunity, barrier function, and host–microbe ecology. Those boundaries have now eroded. It is increasingly clear that mitochondrial function and microbial metabolism are deeply intertwined, not only because microbial metabolites can directly affect mitochondrial pathways, but because mitochondria themselves are products of ancient bacterial endosymbiosis. The cell’s dominant energy organelle is, in evolutionary terms, a domesticated bacterium. That fact matters. It helps explain why microbial signals can regulate mitochondrial behavior so effectively and why disturbances in microbial ecology can reverberate through host bioenergetics, inflammation, and disease [1,5,13-15].

Probiotics sit at the most practical end of this field. They are not the whole microbiome, and they do not replace a healthy diet or ecological diversity, but they can shift microbial metabolic output in meaningful ways. That shift may influence mitochondrial function indirectly through short-chain fatty acids (SCFAs),

antioxidant signaling, cytokine regulation, intestinal barrier integrity, and endotoxin reduction. In some settings, probiotics or postbiotics may also directly affect mitochondrial stress pathways, including mitophagy and mitochondrial redox balance [2-4,7,11].

The importance of this subject extends well beyond the intestine. Mitochondria are central to neuronal survival, skeletal-muscle performance, cardiomyocyte contractility, immune-cell reprogramming, renal tubular integrity, and epithelial barrier repair. If probiotics can alter mitochondrial fitness even modestly, then their relevance spans aging, chronic disease prevention, and adjunctive therapy. The question is not whether every probiotic improves mitochondria; that is clearly false. The real question is which strains, metabolites, doses, and ecological contexts produce clinically relevant mitochondrial effects. This chapter approaches that question by moving from evolutionary principles to mechanistic biology and then into disease-specific and translational implications [1,4,5,8,10,12].

2. Evolutionary foundations of the microbiota–mitochondria axis

Figure 1. Core architecture of the microbiota–mitochondria axis



Figure 1. Core architecture of the microbiota–mitochondria axis. Probiotics alter microbial ecology, which changes metabolite output and, in turn, host signaling pathways that regulate mitochondrial behavior.

The endosymbiotic theory remains one of the most powerful ideas in biology. Mitochondria originated when an ancestral alpha-proteobacterium entered into a long-term symbiotic relationship with a primitive host cell. That event radically increased cellular energy capacity and made complex eukaryotic life possible. Mitochondria still retain bacterial features: a circular genome, bacterial-like ribosomes, double membranes, and respiratory chemistry reminiscent of free-living bacteria. This shared ancestry is not merely historical trivia. It means mitochondria and bacteria are built from overlapping biochemical logics. Both are deeply involved in redox control, membrane energetics, ion gradients, and metabolite sensing [13-15].

The modern gut microbiota can therefore be viewed as an external microbial layer interacting with an internalized ancestral microbe: the mitochondrion. That relationship is not metaphorical. Gut microbes produce compounds that host cells interpret through signaling systems closely tied to mitochondrial metabolism. SCFAs such as butyrate can serve both as energy substrates and signaling molecules. Indole derivatives from tryptophan metabolism influence inflammation and barrier function. Bile-acid transformations alter endocrine and metabolic pathways through receptors that intersect with mitochondrial regulation. Even reactive oxygen species can be understood as a shared signaling language across host and microbial systems [1,5,10,13,14].

This evolutionary framing also helps explain why disruptions in microbial ecology can have system-wide energetic consequences. If the host evolved in continuous metabolic dialogue with commensal microbes, then dysbiosis is not simply a loss of "good bugs." It is a distortion of ancient informational and energetic exchanges. Probiotics, in that sense, are attempts to steer that exchange back toward a more favorable state. They are not magic bullets. They are ecological nudges applied to an evolutionarily old regulatory system [1,5,14,15].

3. Core mitochondrial biology relevant to probiotic action

Mitochondria produce ATP by coupling electron transport to proton pumping and ATP synthase activity across the inner mitochondrial membrane. But energy production is only one dimension of mitochondrial function. Mitochondria regulate calcium handling, apoptosis, innate immunity, steroid synthesis, heat production, intermediary metabolism, and cellular redox tone. Their importance arises from the fact that they sit at the intersection of substrate availability and cellular demand. They constantly "decide" whether to oxidize fatty acids, glucose-derived pyruvate, amino-acid intermediates, or ketone bodies. Those decisions shape whole-cell behavior [1,5,10].

The electron transport chain is also a major source of reactive oxygen species. Under efficient conditions, electrons are transferred along complexes I through IV and ultimately reduce oxygen to water. Under stress, substrate overload, or impaired respiratory efficiency, electrons can leak and form superoxide. That is why mitochondria are both producers and targets of oxidative stress. The cell's antioxidant systems—superoxide dismutase, glutathione peroxidase, catalase, peroxiredoxins, glutathione and thioredoxin networks—exist partly to keep mitochondrial ROS within useful signaling ranges rather than destructive ranges [10,13].

Mitochondria are dynamic networks rather than isolated bean-shaped organelles. They fuse, divide, migrate, exchange contents, and are selectively removed by mitophagy. This dynamic quality matters because mitochondrial health is a moving target. A cell does not simply "have good mitochondria" or "bad mitochondria." It constantly remodels its mitochondrial population in response to energy demand, stress, cytokine signals, and nutrient availability. Probiotic effects on mitochondria must therefore be understood as network effects. The likely result is not a dramatic switch from dysfunction to perfect function. More often, probiotics may slightly improve redox balance, mitophagic efficiency, inflammatory tone, or substrate handling, and over time those small changes can meaningfully alter tissue resilience [1,4,5,7,8,12].

4. Reactive oxygen species, antioxidant defense, and mitochondrial redox balance

The relationship between mitochondria and ROS is often oversimplified. ROS are not merely harmful waste. At physiological levels they function as signals that regulate hypoxic adaptation, immune activity, mitochondrial biogenesis, and stress responses. The problem arises when ROS production persistently exceeds detoxification capacity. That shift damages lipids, proteins, and mitochondrial DNA, creating a self-reinforcing cycle of respiratory dysfunction and oxidative stress. Chronic inflammatory disease, neurodegeneration, insulin resistance, and aging all involve some version of this cycle [10,13-15].

Probiotics may influence this process through at least four routes. First, some strains produce antioxidant metabolites directly, including peptides, exopolysaccharides, and compounds that affect glutathione metabolism. Second, they can alter microbial ecology in ways that increase production of butyrate and related SCFAs, which are linked to improved redox homeostasis. Third, they may reduce inflammatory burden and endotoxin exposure, thereby lowering cytokine-driven mitochondrial stress. Fourth, certain strains and postbiotics appear to activate host antioxidant pathways, particularly NRF2-dependent transcription [3,7,10].

The evidence is strongest in preclinical models. Postbiotics from Lacticaseibacillus casei CRL431 reduced hepatic mitochondrial dysfunction and oxidative stress in aflatoxin-exposed rats, with effects on antioxidant status and mitochondrial preservation [3]. In a severe-burn model, combined sodium butyrate and probiotics reduced oxidative injury and inflammatory signaling in the small intestine while improving pathways involving HMGB1/NF-kB, ERK1/2, and NRF2 [7]. In an Alzheimer-like rodent model, L. acidophilus reduced mitochondrial dysfunction and oxidative stress markers while improving behavioral outcomes [4].

These findings do not prove that every probiotic is an antioxidant therapy. They do show that probiotic or postbiotic interventions can alter the redox environment in ways that plausibly protect mitochondria. For a lay reader, the simplest way to think about it is this: some probiotic interventions appear to reduce the amount of biochemical “friction” inside mitochondria, making energy production less damaging and more stable [3,4,7,10].

5. The AMPK–SIRT1–PGC-1alpha axis and mitochondrial biogenesis

Figure 2. Signaling pathways through which probiotics may influence mitochondria



Figure 2. Signaling pathways through which probiotics may influence mitochondria. SCFAs and related metabolic shifts converge on AMPK, SIRT1, PGC-1α, FOXO, mTOR restraint, and TFAM-linked mitochondrial support.

One of the most important pathways in mitochondrial adaptation is the AMPK–SIRT1–PGC-1alpha axis. AMPK is activated when cellular energy is low relative to demand. It acts as a metabolic emergency brake and reset button, pushing the cell toward energy-generating processes and away from energy-consuming ones. SIRT1, a NAD+-dependent deacetylase, helps translate energy stress into transcriptional reprogramming. PGC-1alpha is the master coactivator that drives mitochondrial biogenesis and oxidative-metabolic remodeling.

SCFAs, especially butyrate, intersect with this axis at multiple levels. They influence substrate availability, redox state, histone acetylation, and AMPK activation. In practical terms, when microbial metabolism favors SCFA production, host cells may receive signals that encourage mitochondrial renewal and metabolic flexibility. This matters in tissues with high energetic demand—skeletal muscle, brain, heart, intestinal epithelium, and kidney [1,5,11,12].

The clearest disease relevance of this pathway is in metabolic dysfunction. In obesity and insulin resistance, mitochondrial fatty-acid handling becomes inefficient, ectopic lipid intermediates accumulate, and the cell gets trapped in a low-flexibility, high-stress metabolic state. In animal models, chronic treatment with prebiotics, probiotics, and synbiotics improved cardiac mitochondrial function and left-ventricular performance in obese insulin-resistant rats [8]. These improvements likely reflect more than one mechanism, but enhanced mitochondrial substrate handling and reduced inflammatory stress are central candidates.

This pathway also links probiotics to aging biology. The same axis activated by exercise, caloric moderation, and metabolic stress can be nudged by microbial metabolites. That does not mean probiotics mimic

exercise or calorie restriction wholesale. It means they may support part of the same adaptive circuitry—specifically the part that renews mitochondria and improves their efficiency [1,5,8,11].

6. mTOR, FOXO, and nutrient-sensing tradeoffs

If AMPK and SIRT1 are often associated with repair, flexibility, and energy efficiency, mTOR is more strongly associated with growth, synthesis, and nutrient abundance. Cells need all of these systems. Problems arise when the balance is distorted. Chronic overnutrition, inflammatory signaling, and insulin resistance can keep mTOR biased toward anabolic pressure while suppressing autophagy and quality-control mechanisms. That state is unfavorable for long-term mitochondrial integrity.

FOXO transcription factors sit on the opposite side of many of these tradeoffs. They are activated under stress, reduced insulin signaling, and energy scarcity. FOXO programs tend to enhance antioxidant defenses, autophagy, DNA repair, and stress resistance. These pathways are heavily implicated in aging and longevity research because they help shift the cell from immediate growth toward preservation and repair.

How do probiotics enter this picture? Mainly through indirect control of nutrient signaling. By improving insulin sensitivity, reducing endotoxemia, increasing SCFA production, and damping chronic inflammation, probiotics may move the cell away from pathological nutrient excess signaling. That can lower chronic mTOR pressure and make FOXO-linked stress adaptation more available. This is still a mechanistic inference in many settings, but it is consistent with the known interaction of microbial metabolites with AMPK, inflammation, and redox signaling [1,5,10,12,15].

For lay readers, the key point is that mitochondria do not respond only to calories. They respond to the quality of the cell's metabolic environment. Probiotics may improve that environment by lowering inflammatory "noise" and producing metabolites that favor repair over metabolic chaos.

7. Mitophagy, mitochondrial dynamics, and the mitochondrial unfolded protein response

Figure 3. Mitochondrial quality-control systems relevant to probiotic action



Figure 3. Mitochondrial quality-control systems relevant to probiotic action. The most plausible effects involve mitophagy, proteostasis, and improved tolerance of metabolic stress.

Healthy mitochondria are maintained not only by making new organelles but also by removing damaged ones. Mitophagy—the selective autophagic removal of impaired mitochondria—is therefore central to mitochondrial quality control. The best known pathway involves PINK1 and Parkin, which mark depolarized mitochondria for degradation. Receptor-mediated pathways involving BNIP3, NIX, and FUNDC1 also contribute under specific conditions such as hypoxia and developmental remodeling.

Mitochondria also undergo fusion and fission, processes governed by proteins such as MFN1, MFN2, OPA1, and DRP1. Fusion can rescue stressed mitochondria by mixing components across the network. Fission can isolate damaged segments so they can be removed. When this choreography fails, cells accumulate fragmented, inefficient, ROS-heavy mitochondrial populations [1,5].

The mitochondrial unfolded protein response, or UPRmt, is another major quality-control system. When misfolded proteins accumulate or mitochondrial proteostasis is stressed, retrograde signals to the nucleus induce chaperones and proteases that help stabilize the organelle. Controlled activation of UPRmt appears to be linked to adaptive stress responses and, in some model systems, longevity.

Evidence that probiotics affect these systems is growing. A particularly interesting study found that Saccharomyces boulardii and Lactococcus lactis could upregulate Parkin-mediated mitophagy in a mitochondrial stress model [16]. That does not yet translate directly into clinical recommendations, but it is

exactly the type of mechanistic link this field needs: a demonstration that probiotic strains can affect genuine mitochondrial quality-control machinery rather than merely broad inflammatory markers [16].

This matters enormously because many chronic diseases are, at least partly, diseases of failed mitochondrial housekeeping. If probiotics can improve mitochondrial "cleanup" even modestly, they may have outsized benefits over time.

8. TFAM, mitochondrial DNA maintenance, and mitonuclear communication

Mitochondrial DNA is vulnerable. It sits close to the respiratory chain, lacks the same packaging environment as nuclear DNA, and is exposed to redox stress. Mitochondrial transcription factor A (TFAM) is crucial because it organizes mtDNA into nucleoids, stabilizes it, and supports replication and transcription. Reduced TFAM expression or impaired mtDNA maintenance contributes to aging, cardiomyopathy, neurodegeneration, and general bioenergetic decline.

Mitonuclear communication refers to the constant coordination between the mitochondrial and nuclear genomes. This is essential because respiratory-chain complexes are assembled from proteins encoded by both genomes. If nuclear and mitochondrial programs drift out of sync, respiratory inefficiency, ROS generation, and stress signaling rise quickly.

Probiotics likely affect this domain mostly upstream, through AMPK–PGC-1alpha signaling, redox control, NAD+ metabolism, and inflammatory modulation. When those systems improve, TFAM expression and mtDNA maintenance may improve as downstream consequences. A direct probiotic-to-TFAM literature is still thin, but the mechanistic bridge is plausible and increasingly relevant, especially in aging and chronic-disease models [1,5,10-12].

9. Aging, inflammaging, and mitochondrial decline

Aging is not a single process. It is a convergence of deteriorating networks: protein homeostasis, stem-cell maintenance, genomic stability, intercellular communication, immune balance, and mitochondrial function. Mitochondria sit at the center of this web because they influence energy availability, ROS production, apoptosis, and inflammatory tone. Age-related mitochondrial decline is characterized by lower respiratory efficiency, greater oxidative stress, poorer mitophagy, and increased mtDNA damage.

At the same time, the gut microbiota changes with age. Diversity often falls, SCFA production may decline, barrier integrity weakens, and inflammatory taxa may expand. The result is a pro-inflammatory milieu sometimes described as "inflammaging." Because mitochondrial dysfunction itself drives inflammatory signaling—through ROS, altered metabolites, and mitochondrial DNA release—the microbiota and mitochondria can amplify each other's age-related deterioration [5,10,13-15].

This is where probiotic strategies become conceptually attractive. They are unlikely to "stop aging," but they may interrupt parts of the inflammaging loop. By supporting barrier integrity, SCFA production, and anti-inflammatory signaling, probiotics may reduce the inflammatory burden placed on mitochondria. By improving mitochondrial resilience, they may also reduce the downstream inflammatory signals generated by damaged organelles.

The deeper point is that aging can be framed partly as loss of network resilience. Probiotic interventions belong in that conversation because they target one of the network's modifiable ecological layers.

10. Neurodegeneration and the gut–brain–mitochondria axis

Figure 4. Organ systems in which mitochondrial effects of probiotics may matter



Figure 4. Organ systems in which mitochondrial effects of probiotics may matter. Mitochondrial responses in the brain, heart, kidney, and intestinal epithelium may help explain why the field spans multiple chronic diseases.

Mitochondria are central to neurodegeneration because neurons are unusually dependent on oxidative phosphorylation, calcium control, and axonal transport. In Alzheimer's disease, mitochondrial dysfunction appears early and involves reduced respiratory capacity, oxidative damage, altered dynamics, and bioenergetic failure. In Parkinson's disease, mitochondrial impairment and defective mitophagy—especially involving PINK1/Parkin pathways—are among the most consistent mechanistic themes.

The gut–brain axis adds a microbiological dimension to this picture. Gut microbial metabolites can affect vagal signaling, neuroinflammation, barrier permeability, circulating cytokines, and substrate supply. Reviews now place mitochondria as key mediators in the microbiota–gut–brain axis rather than as passive downstream targets [1,17].

The Parkinson's model using probiotic AP-32 and A-RM is notable because it showed restoration of energy metabolism, increased SCFAs, improved mitochondrial function, and better motor outcomes after 6-OHDA injury [2]. That is precisely the kind of integrated result this field needs: microbial intervention, metabolite shift, mitochondrial improvement, and functional recovery in the same model [2]. Similarly, in Alzheimer-like models, probiotic L. acidophilus improved behavioral and mitochondrial parameters, supporting the idea that antioxidant and mitochondrial effects can translate into neurobiological outcomes [4].

These models do not prove that probiotics treat Parkinson's or Alzheimer's in humans. But they justify serious translational interest. The mechanistic pathway is coherent: microbial modulation alters metabolite signaling and inflammatory tone, which then affects neuronal mitochondrial resilience.

11. Cardiometabolic disease and insulin-resistant mitochondria

Cardiometabolic disease is a mitochondrial story as much as it is a glucose story. Insulin resistance, fatty-liver disease, central obesity, hypertension, and diabetic cardiomyopathy all involve disturbed mitochondrial substrate handling. Cells become less able to switch efficiently between fuels, more likely to accumulate toxic lipid intermediates, and more vulnerable to ROS and inflammatory signaling.

The microbiota contributes through multiple routes: energy harvest, bile-acid signaling, endotoxin translocation, SCFA production, choline metabolism, and inflammatory priming. Dysbiosis in a high-fat, low-fiber context tends to increase metabolic stress rather than resilience.

The study by Tunapong and colleagues is particularly relevant because chronic prebiotic, probiotic, and synbiotic treatment in obese insulin-resistant rats improved insulin resistance and left-ventricular dysfunction, with cardiac-mitochondrial relevance explicitly discussed in the paper [8]. This matters because the heart is among the most mitochondria-dense tissues in the body. If microbial interventions can reduce mitochondrial strain there, they may have real cardiometabolic significance [8].

Again, the most reasonable interpretation is not that probiotics are stand-alone metabolic cures. Rather, they may improve the metabolic terrain in which mitochondria operate: less endotoxin, less cytokine stress, better SCFA signaling, improved substrate selection, and potentially more effective mitochondrial turnover.

12. Chronic kidney disease and renal mitochondrial vulnerability

The kidney, especially the proximal tubule, is a mitochondrial organ. Tubular cells are heavily dependent on oxidative metabolism, and when mitochondrial function declines, renal injury accelerates. Chronic kidney disease (CKD) involves oxidative stress, inflammation, fibrosis, and accumulation of uremic toxins—all of which are linked to mitochondrial dysfunction.

The gut is highly relevant to CKD because renal dysfunction alters the microbiota, and dysbiosis in turn increases production of uremic and inflammatory metabolites. This bidirectional loop can intensify mitochondrial damage in the kidney.

Park and colleagues showed that Lactobacillus acidophilus KBL409 protected against kidney injury in mice with CKD by improving mitochondrial function [9]. That title alone is unusually direct for this field. It matters because it moves beyond general anti-inflammatory claims and places mitochondrial improvement at the center of the probiotic effect [9]. In practical terms, this suggests that microbial interventions may help preserve renal energy handling and reduce fibrosis-promoting stress.

13. Intestinal barrier injury and the local mitochondrial dimension

Because the intestine is where probiotics act first, local mitochondrial effects matter. Intestinal epithelial cells require substantial ATP to maintain tight junctions, nutrient transport, turnover, and barrier repair. When epithelial mitochondria are stressed—by ischemia, toxins, inflammation, or severe injury—the barrier weakens. That permits more luminal products to cross, escalating immune activation and systemic inflammation.

This is one reason the burn-injury study is so important. Zhou and colleagues found that sodium butyrate plus probiotics ameliorated small-intestinal injury after severe burn, with effects involving inflammatory

pathways and oxidative stress [7]. The implication is that local mitochondrial rescue in the gut may have whole-body consequences, because preserved barrier integrity prevents further inflammatory amplification.

This local-to-systemic logic also applies to inflammatory bowel diseases, infectious injury, and stress-related barrier dysfunction. The gut is not merely a target of probiotics; it is also the launch site from which mitochondrial and immune effects spread systemically.

14. Human translational evidence: what is real, what is not

Human probiotic research is simultaneously promising and frustrating. It is promising because clinical trials often show improvements in inflammatory markers, insulin sensitivity, lipid profiles, oxidative-stress indices, and some cognitive or gastrointestinal outcomes. It is frustrating because most trials do not measure mitochondrial endpoints directly. Instead, they infer mitochondrial relevance from broader metabolic improvements.

That does not make the data worthless. It means the human evidence is usually one inferential step away from what mitochondrial biologists want. Still, the convergence across fields is meaningful: probiotics can improve systemic states that are known to burden mitochondria, and in some contexts those effects are likely mediated through mitochondrial pathways [1,5,10-12].

What is still missing are large, well-designed human studies that combine:
1. defined probiotic strains,
2. careful dietary control,
3. direct mitochondrial measurements,
4. metabolomics,
5. microbiome sequencing, and
6. clinically relevant outcomes.

Until that happens, sweeping claims are not justified. But dismissing the field would also be wrong. There is already enough mechanistic and preclinical coherence to justify serious translational investment.

15. A practical systems model of probiotic mitochondrial support

The simplest complete model looks like this:

A probiotic or probiotic-supported ecosystem shift changes microbial metabolite output.
That changes SCFAs, bile-acid derivatives, indoles, inflammatory products, and barrier dynamics.
Those changes alter host nutrient sensing, redox control, cytokine signaling, and endotoxin exposure.
Those shifts then change mitochondrial biogenesis, ROS balance, quality control, and substrate handling.
Over time, those mitochondrial effects change tissue resilience.

That is a systems model, not a drug model. It does not depend on one receptor or one enzyme. Its strength is that it makes sense of why probiotics may have broad but modest effects across multiple diseases. Its weakness is that broad systems effects are harder to study and standardize than single-target pharmacology.

16. Limits, overclaims, and what must not be said

This field attracts hype because mitochondria and probiotics are both popular topics. That combination makes overclaiming almost inevitable. Several points need to be said plainly.

First, probiotics are not interchangeable. A strain-specific effect in a Parkinsonian rat model does not transfer automatically to all Lactobacillus products, let alone all probiotic supplements.

Second, mitochondrial improvement in preclinical models does not equal disease reversal in humans.

Third, probiotics do not substitute for exercise, diet quality, sleep, or correction of severe metabolic disease.

Fourth, many “mitochondrial” claims in the supplement marketplace are not grounded in direct mitochondrial data.

The scientifically defensible position is narrower and stronger: selected probiotic or postbiotic interventions can influence pathways that matter to mitochondrial health, and in some models they clearly improve mitochondrial function or resilience [2-4,7-9,16].

17. Future directions

The next decade should focus on precision rather than marketing. The field needs:
- strain-level mapping of mitochondrial effects,
- human trials with direct mitochondrial biomarkers,
- integrated metabolomics and microbiome analysis,
- tissue-specific models,
- better diagrams of pathway crosstalk,
- and ecological frameworks that connect diet, exercise, and probiotics rather than treating them separately.

It is also likely that the future belongs not only to classic probiotics but to synbiotics, postbiotics, engineered microbial consortia, and microbiome-informed nutritional designs.

18. Conclusion

The microbiota–mitochondria axis is no longer a speculative metaphor. It is a biologically coherent framework supported by evolutionary logic, mechanistic studies, and a growing body of disease-specific evidence. Probiotics occupy a practical but limited position within that framework. They are not universal mitochondrial medicines, yet under the right conditions they appear capable of improving redox balance, supporting mitochondrial biogenesis, enhancing quality-control pathways, and reducing inflammatory pressure on high-demand tissues.

The most responsible conclusion is neither hype nor dismissal. It is that probiotics may be meaningful mitochondrial modulators when matched correctly to biological context. That makes them scientifically important, clinically plausible as adjunctive tools, and worthy of much better human research than they have received so far [1-16].

References

1. Qiao L, Xie X, Zhou Z, Yang M, Chen D, Li Y. The potential role of mitochondria in the microbiota-gut-brain axis: a narrative review. Pharmacol Res. 2024;208:107372. PMID: 39332752.

2. Nurrahma BA, Tzeng YT, Hsieh SY, Lin WY, Yeh YM, Huang HT, et al. Probiotic supplementation facilitates recovery of 6-OHDA-induced motor deficit via improving mitochondrial function and energy metabolism. Nutrients. 2021;13(6):2071. PMID: 34025392.
3. Guerrero-Encinas I, Nunez N, Castro M, Chaia AP, Gonzalez SN, Zampini IC, et al. Protective effect of Lacticaseibacillus casei CRL 431 postbiotics on mitochondrial function and oxidative status in rats with aflatoxin B1-induced oxidative stress. Food Chem Toxicol. 2021;147:111914. PMID: 33512646.
4. Beltagy DM, Mohamed RH. Beneficial consequences of probiotic on mitochondrial dysfunction associated with Alzheimer's disease. J Mol Neurosci. 2021;71(8):1498-1511. PMID: 33781011.
5. Clark A, Mach N. The crosstalk between the gut microbiota and mitochondria during exercise. Cells. 2017;6(4):52. PMC5437217.
6. Jackson DN, Theiss AL. Gut bacteria signaling to mitochondria in intestinal inflammation and cancer. Gut Microbes. 2020;11(3):285-304. PMC7524274.
7. Zhou B, Yuan Y, Zhang S, Guo C, Li X, Li G, et al. Combination of sodium butyrate and probiotics ameliorates intestinal injury in a rat model of severe burn. Burns. 2022;48(4):845-857. PMID: 34903409.
8. Tunapong W, Apaijai N, Yasom S, Tanajak P, Wanchai K, Chunchai T, et al. Chronic treatment with prebiotics, probiotics and synbiotics attenuates left ventricular dysfunction in obese insulin-resistant rats. Eur J Nutr. 2018;57(6):2091-2104. PMID: 28608320.
9. Park J, Nam KH, Nam BY, et al. Lactobacillus acidophilus KBL409 protects against kidney injury via improving mitochondrial function with chronic kidney disease. Eur J Nutr. 2024;63(6):2121-2135. PMID: 38705901.
10. Ballard JWO, Towarnicki SG. Mitochondria, the gut microbiome and ROS. Cell Signal. 2020;75:109737. PMID: 32810578.
11. Zachos KA, Wiler JL, Vavougios GD, et al. The interplay between mitochondria, the gut microbiome and diet in mitochondrial disease. Front Physiol. 2024;15:1415236. PMC11306032.
12. Nicese MN, et al. Sodium butyrate as key regulator of mitochondrial function and barrier integrity. Cell Mol Life Sci. 2023;80:266. PMC10487840.
13. Saint-Georges-Chaumet Y, Edeas M. Microbiota-mitochondria inter-talk: consequence for microbiota-host interaction pathophysiology. Mitochondrion. 2016;26:7-14. PMID: 26500226.
14. Yardeni T, Tanes C, Bittinger K, Mattei LM, Schaefer PM, Singh LN, et al. Host mitochondria influence gut microbiome diversity. Proc Natl Acad Sci U S A. 2019;116(41):20419-20425. PMID: 31266851.
15. Zachos KA? no duplicate maybe use review
15. Gupta P, et al. Interconnection between gut microbial metabolites and mitochondrial ROS in health and disease. Free Radic Biol Med. 2024. PMID: 41028649.
16. Hawrysh PJ, et al. PRKN/parkin-mediated mitophagy is induced by probiotics during mitochondrial stress. Autophagy. 2023. PMID: 36708254.

Table 1. Representative probiotic or microbiota-linked studies with mitochondrial relevance

Study	Model	Mitochondrial theme	Main implication
Nurrahma et al. [2]	6-OHDA Parkinsonian rat model	Energy metabolism, SCFAs, mitochondrial function	Probiotic supplementation improved motor recovery and mitochondrial-linked outcomes.
Guerrero-Encinas et al. [3]	Aflatoxin oxidative-stress rat model	Hepatic mitochondrial dysfunction, antioxidant status	L. casei CRL431 postbiotics reduced oxidative injury and protected mitochondria.
Beltagy & Mohamed [4]	Alzheimer-like rodent model	Mitochondrial dysfunction, antioxidant effects	L. acidophilus improved mitochondrial measures and cognitive-related outcomes.
Zhou et al. [7]	Severe-burn intestinal-injury rat model	Oxidative stress, inflammatory signaling, tissue injury	Sodium butyrate plus probiotics protected the intestine in a mitochondria-relevant setting.
Tunapong et al. [8]	Obese insulin-resistant rats	Cardiac mitochondria, LV dysfunction	Pre/pro/synbiotic treatment improved insulin resistance and heart function.
Park et al. [9]	Mouse chronic kidney disease model	Kidney mitochondrial function	KBL409 protected against kidney injury through mitochondrial improvement.
Hawrysh et al. [16]	Cellular mitochondrial-stress model	Parkin-mediated mitophagy	Specific probiotic strains enhanced mitophagy signaling.